Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-389949 single-ascending-dose and food-effect study in healthy male volunteers
NL-OMON35247Active, not recruiting
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in Inflammatory Disorders comparing ACT-389949 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Nov 2011; status: active, not recruiting.
02
Drugs
ACT-389949
03
Conditions
Inflammatory Disorders
Beyond the preview
Go deeper on NL-OMON35247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35247.